A COHORT STUDY ON THE CANCER INCIDENCE IN AN AREA WHERE HTLV I, HCV AND HBV ARE ENDEMIC

HTLV I、HCV 和 HBV 流行地区癌症发病率的队列研究

基本信息

批准号：
14570342
负责人：
ARISAWA Kokichi
金额：
$ 1.6万
依托单位：
Nagasaki University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2003
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14570342/
关键词：
HTLV-1 HCV HBV Cohort study Cancer Incidence Liver cancer 交互作用胃がん

项目摘要

(1) Interleukin-10 promoter polymorphism and liver fibrosis progression in patients with chronic hepatitis C in Japan.We examined the inheritance of three biallelic polymorphisms in the IL-10 gene promoter, at positions -1082, -819, and -592 from the transcription start site, which produce three different haplotypes, in 52 healthy subjects and 114 patients with post-transfusion hepatitis C. Patients were classified into slow or no-progression group (34 patients), intermediate progression group (33 patients) and rapid progression group (47 patients), based on the degree of fibrosis of liver biopsy specimens : The slow progression group had the putative high IL-10 producing GCC haplotype more often than, the intermediate and rapid progression groups (p<0.01). Individuals with the GCC haplotype were more likely to have less hepatic fibrosis than individuals with the ATA or ACC haplotypes (odds ratio 0.1, 95% confidence interval 0.01-0.9). These results indicate that, in chronic hepatitis … More C, the putative high IL-10 production haplotype GCC is associated with inhibition of the progression of liver fibrosis.(2)The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.Background : Des-gamma-carboxy prothrombin (DCP) has been reported to be an important prognostic factor in patients with hepatocellular carcinoma (HCC). Recently, a monoclonal antibody, 19B7, which recognizes the Gla domain of. DCP, has been identified. The 19B7 antibody recognizes an epitope different from that recognized by MU-3, which is another antibody against DCP. In this study, the authors investigated the measurement of DCP using the antibodies MU-3 and 19B7, respectively, as a prognostic factor for patients with HCC who had solitary, small tumors and or Child Stage AHCC.Methods : One hundred four patients with HCC who had solitary, small tumors or Child Stage A tumors were enrolled in the study between 1991 and 2001. All patients were treated and were followed for a mean of 3.2 years. The authors analyzed the correlation between the DCP Index (DCP measured by MU-3 and DCP measured by 19B7) and patient prognosis. The patients were classified into 3 groups based on their DCP Index :1) DCP negative (DCP<40 milli arbitrary unit (mAU)/mL)), 2)low DCP Index (DCP> or = 40mAU/mL ; MU-3:19B7 ratio, <3.0, and-3) high DCP Index (DCP> or 40mAU/mL ; MU-3:19B7 ratio, > or= 3.0).Results : The survival rate for patients in the high DCP Index group was lower compared with the survival rate for patients in the DCP-negative group and was significantly lower compared with the survival rate for patients in the low DCP Index group. In a univariate Cox proportional hazards model, the positive factors were high DCP Index and low DCP Index. Among the positive predictive factors that were analyzed using a multivariate Cox proportional hazards model were age (hazard ratio, 3.27; P=0.006), low DCP Index (hazard ratio, 2.87; P=0.012), and high DCP Index (hazard ratio, 12.3, P<0.0001).Conclusions : The prognosis of patients who had a high DCP Index score was poorer compared with patients who had a low DCP Index score and patients who were classified as DCP negative. The authors concluded that the DP Index is a prognostic indicator for patients with HCC. Copyright 2003 American Cancer Society.(3)Human T lymphotropic virus type-I infection, survival and cancer risk in southwestern Japan : A prospective cohort study.Objectives : This study prospectively evaluated the associations of HTLV I infection with survival and cancer incidence.Methods : The study base comprised 4,297 adults (aged 40-69 years in 1993) who had either visited the outpatient clinic or who had received annual health check-ups at the A Hospital, Nagasaki, Japan, between 1985 and 1992 (HTLV I seropositivity=24.7%). During the follow-up period (1993-1999 or 2000), 290 deaths and 261 cases of malignant neoplasms occurred, including 10 deaths and six incident cases of adult T -cell leukemia/lymphoma (ATL).Results : After adjustment for gender, age and other covariates, HTLV-I seropositivity was associatedd with an increased mortality from all-causes excluding ATL (rate ratio [RR] 1.3, 95% confidence interval [CI] 1.0-1.7), all non-neoplastic diseases (RR 1.6, 95% CI 1.1-2.3) and heart diseases. HTLV I infection was not found to be associated with an increased risk of developing total cancers other than ATL (RR 0.97, 95% CI 0.73-1.3), colorectal cancers, liver cancer or lung cancer, but was associated with a reduced risk of gastric cancer, (RR=0.42, 95% CI 0.18-0.99).Conclusions : HTLV I infection is associated with increased mortality from all-causes excluding ATL and all non-neoplastic diseases. HTLV I carriers may not be at increased general cancer risk, but at reduced risk of gastric cancer. Less

（1）日本慢性丙型肝炎患者的白细胞介素-10启动子多态性和肝纤维化进展。我们在IL -10启动子中遗传了三个不同的患者，在IL -10 Gene启动子中遗传了IL -10基因启动子中的IL -10基因启动子的遗传。 post-transfusion hepatitis C. Patients were classified into slow or no-progression group (34 patients), intermediate progression group (33 patients) and rapid progression group (47 patients), based on the degree of fibrosis of liver biopsy specimens: The slow progression group had the putative high IL-10 production GCC haplotype more often than, the intermediate and rapid progression groups (p<0.01).与具有ATA或ACC单倍型的个体相比，具有GCC单倍型的个体的肝纤维化更可能更小（优势比0.1，95％置信区间0.01-0.9）。 These results indicate that, in chronic hepatitis … More C, the putative high IL-10 production haplotype GCC is associated with inhibition of the progression of liver fibrosis.(2)The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.Background : Des-gamma-carboxy prothrombin (DCP) has been reported to be an important肝细胞癌（HCC）患者的预后因子。最近，一种单克隆抗体，19B7，它认识到GLA域的。 DCP已被确定。 19B7抗体识别出与MU-3识别的表位，这是另一种针对DCP的抗体。在这项研究中，作者分别使用抗体MU-3和19B7研究了DCP的测量，作为HCC患者的预后因素，该患者具有固体，小肿瘤和或儿童阶段Ahcc.Methods：一百四个患有稳固的HCC患者，患有固体，小型肿瘤或儿童肿瘤的HCC患者在研究中均在研究中均在研究中均在1991年和2001年均在1991年和2001年。作者分析了DCP指数（通过19B7测量的MU-3和DCP测得的DCP）与患者预后之间的相关性。 The patients were classified into 3 groups based on their DCP Index :1) DCP negative (DCP<40 milli arbitrary unit (mAU)/mL)), 2)low DCP Index (DCP> or = 40mAU/mL; MU-3:19B7 ratio, <3.0, and-3) high DCP Index (DCP> or 40mAU/mL; MU-3:19B7 ratio, > or= 3.0）。分辨率：与DCP阴性组患者的存活率相比，高DCP指数组患者的存活率较低，并且与低DCP指数组患者的存活率相比，患者的存活率显着降低。在单变量的COX比例危害模型中，阳性因素是DCP高指数和低DCP指数。在使用多变量COX比例危险模型分析的积极预测因素中，危险比率为3.27； P = 0.006），低DCP指数（危险比，2.87; P = 0.012）和DCP指数高（危害比率较高，危害比率，12.3，p <0.0001）。 DCP指数评分较低的患者和被归类为DCP阴性的患者。作者得出的结论是，DP指数是HCC患者的预后指标。版权2003年美国癌症学会。（3）日本西南部的人类T型淋巴病毒感染，生存和癌症风险：一项前瞻性研究。目标研究：前瞻性地评估了HTLV I感染与生存和癌症事件的相关性。 1985年至1992年之间，诊所或在日本长崎的A医院接受了年度健康检查（HTLV I血清阳性= 24.7％）。在随访期（1993-1999或2000年）中，发生了290例死亡和261例恶性肿瘤，其中包括10例死亡和6例成人T-Cell白血病/淋巴瘤（ATL）的事件（ATL）。消除：调整后，与其他共和力相关的性别，与其他共同估计相关的性别率是增加的，这是增加了估计性的估计率（ [RR] 1.3，95％置信区间[CI] 1.0-1.7），所有非塑性疾病（RR 1.6，95％CI 1.1-2.3）和心脏病。 HTLV I感染没有发现与ATL以外的其他癌症（RR 0.97，95％CI 0.73-1.3），有色癌症，肝癌或肺癌的风险增加有关，但与胃癌的风险降低有关（RR = 0.42，95％CI 0.42，95％CI 0.18-0.99）。所有因素不包括ATL和所有非塑性疾病。 HTLV I携带者可能没有增加一般癌症风险，而是胃癌风险降低。较少的